GNL Gut and Liver
  1. Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian. Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review. Arch Microbiol 2023;205
    https://doi.org/10.1007/s00203-023-03590-0
  2. Seung Hwan Shin, Sang Hyoung Park. Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2022;80:51
    https://doi.org/10.4166/kjg.2022.096
  3. Eun Ae Kang, Jae Hee Cheon. Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gut and Liver 2022;16:501
    https://doi.org/10.5009/gnl220186
  4. Aneeda Khraibet Abed, Zaytoon A Alkhafaji, Ali Jaber Abood. Serological detection of hepatitis B virus e antigen and TNF-α in a dialysis patient. MJBL 2023;20:771
    https://doi.org/10.4103/MJBL.MJBL_342_23
  5. Nina Jahnich, Peter D. Arkwright. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review. Front. Pharmacol. 2023;14
    https://doi.org/10.3389/fphar.2023.1046306
  6. Yujie Qin, Wenxiu Zhou, Xingnian Zhou, Hong Li. Case report: Recombinant human type II tumour necrosis factor receptor-antibody fusion protein induced occult hepatitis B virus reactivation leading to liver failure. J Int Med Res 2024;52
    https://doi.org/10.1177/03000605241252580
  7. Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im. Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting. Intest Res 2023;21:353
    https://doi.org/10.5217/ir.2023.00013
  8. Ciro Celsa, Giacomo E. M. Rizzo, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Gabriele Rancatore, Pietro Graceffa, Giuseppe Falco, Salvatore Petta, Giuseppe Cabibbo, Vincenza Calvaruso, Antonio Craxì, Calogero Cammà, Vito Di Marco. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis. Liver International 2024
    https://doi.org/10.1111/liv.16064
  9. Yoo Jin Lee, Eun Soo Kim. Vaccination strategies for Korean patients with inflammatory bowel disease. Korean J Intern Med 2022;37:920
    https://doi.org/10.3904/kjim.2022.149
  10. Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia. Biomedicine & Pharmacotherapy 2023;157:114081
    https://doi.org/10.1016/j.biopha.2022.114081
  11. Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res 2023;21:392
    https://doi.org/10.5217/ir.2022.00094
  12. Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow. Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study. Vaccines 2024;12:364
    https://doi.org/10.3390/vaccines12040364
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd